Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Thursday

Key Points

• Q1 2026 earnings due May 14 — Spyre is set to report results after the close on Thursday, May 14, with analysts expecting EPS of ($0.66) and revenue of about $70.9 million; the company missed last quarter’s consensus (reported ($0.74) vs. ($0.66)).
• Wall Street sentiment is broadly bullish with multiple firms raising price targets (several to the $80–$90 range) and a consensus price target of $89.08, giving the stock an overall "Buy" rating.
• Material insider selling occurred on May 1 under 10b5‑1 plans (insiders sold 153,791 shares totaling about $9.8 million in the last 90 days), though insiders still own 15.69% and institutional investors hold roughly 80.4% of the stock.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) is expected to announce its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $70.8710 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:00 AM ET.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.08). On average, analysts expect Spyre Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Spyre Therapeutics Stock Performance

SYRE stock opened at $73.00 on Thursday. The company's 50 day moving average price is $52.88 and its 200 day moving average price is $38.31. Spyre Therapeutics has a fifty-two week low of $12.28 and a fifty-two week high of $76.00. The firm has a market capitalization of $5.75 billion, a price-to-earnings ratio of -35.10 and a beta of 3.12.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on SYRE shares. Deutsche Bank Aktiengesellschaft upped their target price on shares of Spyre Therapeutics from $55.00 to $88.00 and gave the stock a "buy" rating in a research note on Tuesday, April 14th. Wedbush increased their price objective on Spyre Therapeutics from $65.00 to $80.00 and gave the company an "outperform" rating in a report on Monday, April 13th. Wells Fargo & Company increased their price objective on Spyre Therapeutics from $50.00 to $90.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 14th. Jefferies Financial Group increased their price objective on Spyre Therapeutics from $47.00 to $85.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Finally, Wall Street Zen cut Spyre Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, April 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Spyre Therapeutics currently has an average rating of "Buy" and a consensus price target of $89.08.

Insiders Place Their Bets

In other Spyre Therapeutics news, CFO Scott L. Burrows sold 12,500 shares of the firm's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $71.37, for a total value of $892,125.00. Following the sale, the chief financial officer directly owned 97,994 shares of the company's stock, valued at approximately $6,993,831.78. This trade represents a 11.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 78,333 shares of the firm's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $71.50, for a total value of $5,600,809.50. Following the completion of the transaction, the insider owned 78,333 shares in the company, valued at approximately $5,600,809.50. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 153,791 shares of company stock valued at $9,805,860. Insiders own 15.69% of the company's stock.

Institutional Investors Weigh In On Spyre Therapeutics

Several hedge funds have recently modified their holdings of SYRE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Spyre Therapeutics by 18.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,018 shares of the company's stock worth $442,000 after purchasing an additional 4,277 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Spyre Therapeutics by 13.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 47,279 shares of the company's stock worth $708,000 after acquiring an additional 5,723 shares during the period. Rhumbline Advisers boosted its position in Spyre Therapeutics by 30.6% during the 2nd quarter. Rhumbline Advisers now owns 73,168 shares of the company's stock worth $1,095,000 after acquiring an additional 17,145 shares during the period. New York State Common Retirement Fund raised its stake in shares of Spyre Therapeutics by 61.4% in the 2nd quarter. New York State Common Retirement Fund now owns 16,565 shares of the company's stock worth $248,000 after buying an additional 6,300 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Spyre Therapeutics by 37.6% in the 2nd quarter. Invesco Ltd. now owns 34,680 shares of the company's stock worth $519,000 after buying an additional 9,473 shares in the last quarter. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.